Related Experiment Video
Updated: Aug 29, 2025

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies
Mateo Porres-Aguilar1, Debabrata Mukherjee2, S Claudia Didia1
1Department of Internal Medicine, Divisions of Hospital and Adult Clinical Thrombosis Medicine, Texas Tech University Health Sciences Center and Paul L. Foster School of Medicine, El Paso, TX, USA.
Insights
COVID-19 increases the risk of venous thromboembolism (VTE) in hospitalized patients. This review examines thromboprophylaxis strategies and discusses anticoagulation controversies, especially for moderate COVID-19 cases.
Area of Science:
- Internal Medicine
- Cardiology
- Pulmonology
Background:
- COVID-19 is a significant risk factor for venous thromboembolism (VTE).
- Hospitalized patients with moderate to severe/critical COVID-19 face elevated VTE risks.
- Understanding optimal VTE prevention is crucial for patient outcomes.
Purpose of the Study:
- To review current thromboprophylaxis strategies for COVID-19 patients.
- To discuss controversies surrounding anticoagulation in VTE prevention.
- To offer a perspective on managing VTE risk in moderately ill COVID-19 patients.
Main Methods:
- Literature review of emerging data on thromboprophylaxis.
- Analysis of current anticoagulation guidelines and practices.
- Discussion of clinical controversies and expert opinion.
Main Results:
- COVID-19 is strongly associated with increased VTE risk.
- Various thromboprophylaxis strategies are under investigation.
- Debate exists regarding the optimal intensity and duration of anticoagulation, particularly in moderate cases.
Conclusions:
- Effective VTE prophylaxis is essential for hospitalized COVID-19 patients.
- Further research is needed to clarify optimal anticoagulation strategies.
- Personalized approaches may be necessary for managing VTE risk in different COVID-19 severity groups.
Abstract:
Novel coronavirus 2019 (COVID-19) represents a significant risk factor for the development of venous thromboembolism (VTE) in hospitalized with both moderate and severe/critical COVID-19. Herein, we present a brief updated review on emerging robust data on diverse thromboprophylaxis strategies used to mitigate VTE complications, as well as a personal point of view of current controversies in regards the use of therapeutic and prophylactic anticoagulation strategies, particularly in the moderately-ill subgroup of patients with COVID-19.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome IV: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins

